These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36655579)

  • 1. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.
    Coerts HI; de Keizer B; Marlowe RJ; Verburg FA
    Eur J Endocrinol; 2023 Feb; 188(2):. PubMed ID: 36655579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
    Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
    Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
    Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
    Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
    Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
    Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
    Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
    Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
    J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
    Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
    Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
    Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
    Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.
    Tala H; Robbins R; Fagin JA; Larson SM; Tuttle RM
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2105-11. PubMed ID: 21565788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
    Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
    Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
    Fu H; Ma C; Tang L; Wu F; Liu B; Wang H
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human thyrotropin versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer: Experience in a South Taiwanese medical center.
    Tsai JR; Wu ST; Chi SY; Yang YT; Chan YC; Lim LS; Chiew YEW; Chen WC; Chen YN; Chou CK
    Kaohsiung J Med Sci; 2023 Feb; 39(2):175-181. PubMed ID: 36448726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal.
    Hong CM; Kim CY; Son SH; Jung JH; Lee CH; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
    Ann Nucl Med; 2017 Oct; 31(8):582-589. PubMed ID: 28677070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.